Liam Kelly - Enovis Corp Independent Director
| ENOV Stock | USD 48.27 1.60 3.43% |
Insider
Liam Kelly is Independent Director of Enovis Corp since 2020.
| Age | 54 |
| Tenure | 4 years |
| Address | 2711 Centerville Road, Wilmington, DE, United States, 19808 |
| Phone | 302 252 9160 |
| Web | https://www.enovis.com |
Enovis Corp Management Efficiency
Return On Tangible Assets is likely to climb to -0.02 in 2024. Return On Capital Employed is likely to climb to -0.02 in 2024. At this time, Enovis Corp's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 1.3 B in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 85.7 M in 2024. Enovis Corp's management efficiency ratios could be used to measure how well Enovis Corp manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lakshmanan Kannappan | Healthcare Triangle | 57 | |
| Jon Hunt | Heartbeam | 68 | |
| Branislav Vajdic | Heartbeam | 69 | |
| BSN JD | Nutex Health | N/A | |
| Shibu Kizhakevilayil | Healthcare Triangle | 52 | |
| Ryan Bond | Aclarion | 52 | |
| Daniel Tan | EUDA Health Holdings | 43 | |
| Richard Brounstein | Heartbeam | 74 | |
| LaChoenda Rosales | Nutex Health | N/A | |
| Elizabeth Hall | Nutex Health | N/A | |
| Sudish Mogli | Healthcare Triangle | 55 | |
| Steven Sobak | EUDA Health Holdings | 78 | |
| Denise Pufal | Nutex Health | N/A | |
| Michael Gill | Healthcare Triangle | 46 | |
| MD MBA | Nutex Health | 51 | |
| Wei Chen | EUDA Health Holdings | 39 | |
| FACC MD | Heartbeam | 65 | |
| Jon Bates | Nutex Health | 54 | |
| Ken Persen | Heartbeam | N/A | |
| John Lorbiecki | Aclarion | 61 | |
| Kristi Lane | Healthcare Triangle | N/A | |
Management Performance
| Return On Equity | -0.0356 | ||||
| Return On Asset | 0.0037 |
Enovis Corp Leadership Team
Elected by the shareholders, the Enovis Corp's board of directors comprises two types of representatives: Enovis Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enovis. The board's role is to monitor Enovis Corp's management team and ensure that shareholders' interests are well served. Enovis Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enovis Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Macek, VP Relations | ||
| Angela Lalor, Director | ||
| John Kleckner, Principal Officer | ||
| Bradley Tandy, Senior Vice President General Counsel, Corporate Secretary | ||
| Christopher Hix, Chief Financial Officer, Executive Vice President - Finance | ||
| Phillip Berry, Senior CFO | ||
| Liam Kelly, Independent Director | ||
| Rajiv Vinnakota, Independent Director | ||
| Derek JD, Vice Relations | ||
| Louie Vogt, Group Reconstructive | ||
| A Perfall, Independent Director | ||
| Brian Hanigan, Secretary | ||
| Patricia Lang, Chief Human Resource Officer, Senior Vice President | ||
| Mitchell Rales, Chairman of the Board | ||
| Christine Ortiz, Director | ||
| Terry Ross, Group Recovery | ||
| Sharon Wienbar, Independent Director | ||
| Katie Sweet, Vice Communication | ||
| Derek Leckow, Vice Relations | ||
| Barbara Bodem, Director | ||
| Bradley JD, Senior Officer | ||
| Philip Okala, Independent Director | ||
| Brady Shirley, President, Chief Operating Officer, Director | ||
| Matthew Trerotola, Chief Executive Officer, Director | ||
| Tim Czartoski, President Technologies | ||
| Daniel Pryor, Executive Vice President - Strategy and Business Development | ||
| Shyam Kambeyanda, Executive Vice President, President and Chief Executive Officer of ESAB |
Enovis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enovis Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0356 | ||||
| Return On Asset | 0.0037 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 3.99 B | ||||
| Shares Outstanding | 55.88 M | ||||
| Shares Owned By Insiders | 0.90 % | ||||
| Shares Owned By Institutions | 99.10 % | ||||
| Number Of Shares Shorted | 4.76 M | ||||
| Price To Earning | 9.48 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Enovis Stock Analysis
When running Enovis Corp's price analysis, check to measure Enovis Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enovis Corp is operating at the current time. Most of Enovis Corp's value examination focuses on studying past and present price action to predict the probability of Enovis Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enovis Corp's price. Additionally, you may evaluate how the addition of Enovis Corp to your portfolios can decrease your overall portfolio volatility.